A Phase 2, Randomized, Observer-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age.

Trial Profile

A Phase 2, Randomized, Observer-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Typhoid vaccine Vi conjugate (Primary) ; Typhoid vaccine Vi-polysaccharide
  • Indications Typhoid
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 12 Oct 2012 New source identified and integrated (extension trial: EudraCT2011-001448-31).
    • 12 Oct 2012 New source identified and integrated (extension trial: EudraCT2011-001448-31).
    • 09 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (Extension trial: NCT01438996).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top